Q2 FY2026 EarningsQ2 FY26 missed consensus estimates on the bottom line, with a GAAP net loss of $20.7M compared to the $19.5M expected, and a GAAP EPS of -$4.88 vs. -$0.75 expected. Revenue of $0.45M was recognized from the EndPath collaboration, while consensus had anticipated no revenue ($0). Operating expenses surged 34% YoY to $22.3M, primarily driven by a 39% increase in R&D spending to support clinical progress for ATTO-1310 and IND-enabling studies for ATTO-2306 and ATTO-1091.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Attovia Therapeutics(ATTO) the Revenue is 450 K (--%), Beat estimate;the EBIT is -21.8 M (--%), Beat estimate;the EPS is -4.88 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.02B--
-0.02B--
+0.00B--%
EPSMiss expectations
-4.88--
-2.0439--
-2.8361--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf